anacor pharmaceuticals inc
(ANAC:NASDAQ GM)
anacor pharmaceuticals inc (ANAC) Snapshot
|
Open
$5.46
|
Previous Close
$5.49
|
|
|
Day High
$5.68
|
Day Low
$5.40
|
|
|
52 Week High
04/19/13 - $8.25
|
52 Week Low
02/27/13 - $3.00
|
|
|
Market Cap
221.5M
|
Average Volume 10 Days
496.6K
|
|
|
EPS TTM
$-1.71
|
Shares Outstanding
40.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
anacor pharmaceuticals inc (ANAC) Related Businessweek News
No Related Businessweek News Foundanacor pharmaceuticals inc (ANAC) Details
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.
anacor pharmaceuticals inc (ANAC) Top Compensated Officers
anacor pharmaceuticals inc (ANAC) Key Developments
Anacor Pharmaceuticals, Inc. announced unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, total revenues were $1,708,000 compared to $2,417,000 a year ago. Loss from operations was $14,167,000 compared to $13,681,000 a year ago. Net loss was $15,078,000 or $0.42 basic and diluted per share compared to $14,327,000 or $0.48 basic and diluted per share a year ago. The decrease in revenues from 2012 is primarily due to a decrease in research work performed under research and development agreements, including agreements with not-for-profit organizations for neglected diseases. In addition, in the first quarter of 2013, did not recognize any revenue from the upfront free received in 2011 under the agreement with Medicis relating to the discovery of potential treatments for acne. The company expects to initiate a Phase 3 study in atopic dermatitis in the fourth quarter of 2013 or the first quarter of 2014, with timing dependent on the completion of the MUSE study.
Anacor Pharmaceuticals, Inc., Q1 2013 Earnings Call, May 09, 2013
Anacor Pharmaceuticals, Inc. announced that they will report Q1, 2013 results at 4:00 PM, US Eastern Standard Time on May 09, 2013
| Recently Viewed | |||
| ANAC:US | $5.47 USD | -0.02 | |
| Company | Last | Change | |
| No competitor information is available for ANAC. | |||
| View Industry Companies | |||
Industry Analysis
ANAC
Industry Average
| Valuation | ANAC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 20.3x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 17.3x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








